{
  "doc_id": "Determina_33-2024_Lumykras",
  "created_date": "2024",
  "country": "IT",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "AG FA DET Ricl dell (Det (GU Vi reca corr modi l'Ag disp Serv Vi salu dell sull farm sett nove genn Mini pubb genn Vi dell pubb Gazz GENZIA ITALIANA DEL ARMACO TERMINA 17 maggio 2024 lassificazione del medicinale per uso umano Lumykras, within the meaning of Article 8, paragraph 10, of the law of 24 December 1993, n. 537. terminating with n. 33/2024). (24A02603) U n. 121 of 25-5-2024)",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "IL PRESIDENTE is Article 48 of Decree-Law No 269 of 30 September 2003, which provides that:",
      "text": "Prior to Urgent provisions to promote the development and adjustment of public accounts, converted into law No 326 of 24 November 2003, which established the Italian Pharmaceutical Agency and, in particular, paragraph 33 thereof, which lays down the negotiation of the price for products reimbursed by the National Health Service between the Agency and the producers; this is the decree of 20 September 2004, No 245 of the Minister of the Interior, in agreement with the Ministers of the Public Service and the Economy and Finance, recante Reglamento recante l'organizzazione e il funzionamento dell'Agenzia italiana del maco, a norma dell'art. 1/5 Having regard to the decree of the Minister of Health of 5 April 2024 by which, as from the same date, Prof. Robert Giovanni Nistico was appointed President of the Consiglio di Amministrazione dell'Agenzia italiana del farmaco, pursuant to Article 7 of the aforementioned Decree of 20 September 2004, No. 245 and successive modifications; having regard to its decree on 9 February 2024 nominating Dr. Pierluigi Russo as Technical and Scientific Director of the Italian Agency for Pharmaceuticals in accordance with Article 10-bis of the above-mentioned Decree, no. 245, dated 28 May 2020; Having regard to the decision of the Director-General No 643 of 28 May 2020 conferring on Dr Trotta Francesco the position of Head of the HTA and Pharmaceutical Economy Sector; having regard to Law No 537 of 24 December 1993 concerning 'Interventi correttivi di finanza pubblica', with particular reference to Article 8 (10) thereof, which provides for the classification of medicinal products supplied by the Servizio sanitario nazionale (National Health Service); having regard in particular to the Law of 14 December 2000 No 376, recante 'Disciplina della tutela sanitaria delle attività sportive e della lotta contro il doping' (Discipline of the health protection of sports activities and of the fight against doping); having considered Article 48 (3) of Decree-Law No 269 of 30 September 2003, converted, with modifications, by Law No 326 of 24 November 2003, on special medical devices subject to a reimbursement of medical expenses in the context of the monitoring of advanced medical devices; and to Regulation (EC) No 1394/2007 of the European Parliament and Council of 13 November 2007 amending Regulation (EEC) No 2001/83 on the marketing of medicines for human use ('), Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing the European Medicines Agency; having regard to Legislative Decree No 219 of 24 April 2006 implementing Directive 2001/83/EC (and subsequent directives amending it) on a Community code relating to medicinal product for human use; to Decree of the Italian Minister for Health of 2 August 2019 establishing criteria and modalities by which the Italian Agency for Medicinal Products determines, through negotiation, the prices of pharmaceutical products reimbursed by the Servizio Sanitario Nazionale, published in the Official Gazette of the Republic of Italy (Serie Generale No 185 of 24 July 2004); to Decision No 488 of 30 November 2012 on the conversion of the high-level reimbursements to the integrated level of the Paediatric Healthcare Services into a law on the protection of the healthcare market (LIFE), as amended by Decree-Law No 489 of 26 July 2003); 326 (Prontuario farmaceutico nazionale 2006) , published in the Gazzetta Ufficiale della Repubblica italiana - Serie generale - no. 156 of 7 July 2006; Vista la determina AIFA of 27 September 2006, recante Manovra per il governo della spesa farmaceutica convenzionata e non convenzionale, publish in the Gazetta Uffiziale della Repubblica Italiana - serie generale - No. 227 of 29 September 2006; View the determination of the AIFA no. 49/2022 of 1 April 2022, published in die Gazzeta Ufficiali della Repubblica italiana - série generale no. 109 of 11 May 2022 Classification, in accordance with article 12, paragraph 5, of the law of 8 November 2012, no. 189, of the medicinal product for human use \"Lumetras\", approved by the central regulatory authority; Vista the application submitted on 1 February 2022 with the date of publication of the final decision of the European Medicines Agency. (PVC/PE/PVDC/alu)  240 compresse - A.I.C. no. 049858018/E (in base 10) - class of reimbursability: H - ex-factory price (VAT excluded) euro 7.368,00 - price to the public (VAT included) euro 12.160,24;  120 mg - compressed rivestita con film - oral use - flacon (HDPE) 240 (2 × 120) compresse- A. I. C. no .0498032/E (In base 10) di classe di rimborsabilità prezzo: H- factory ex-escusa (Tax) 7.368 euro,00 - public price (TVA included) 12.240,00; (PVP/PE /alu) 10 - class de reimborsability: C. E. 244980/C. The company shall, subject to the provisions relating to the reduction of stocks, in accordance with Article 13 of the Decree-Law of 30 April 2019, No 35, converted, with modifications, into the Law of 25 June 2019, No 60, if it undertakes to maintain a cost supply adequate to the requirements of the National Health Service. Validity of the contract: twenty-four months. For the purposes of prescribing and dispensing medicinal products, doctors and pharmacists affiliated to centres specifically designated by the regions shall compile the computerised data collection form available for access through the AIFA institutional website at the following web address: The classification of 'Lumykras' (prescription medicinal products marketed to the general public by specialists - onco La presente detezione pubblicazione nel sara' notificata all'immissione in Roma, 17 maggificazione ai fini della fornitura aione dei fornitura di rasib) is as follows: medicinale ica limitativa, da rinnovare volt lico suzione di centri ospedali ologo (RNRL). Disposizioni finali ha effetto ermina giorno successo la Gazzetta Ufficiale della Repubblica a tutta la societa' titolare dell'Istituto del Commercio I. 2024 a/sservo a presidente/a generale dell'Ufficio di Medicina Italiana per l'autorizzazione e per il suo uso, per il soggetto a tale autorizzazione: N.S.C.",
      "start_page": 1,
      "end_page": 5
    }
  ],
  "_translation_metadata": {
    "processing_timestamp": "2025-08-11T12:17:16.146163",
    "source_file": "Determina_33-2024_Lumykras_cleaned.json",
    "detected_language": "it",
    "was_translation_needed": true,
    "translation_strategy": "nllb_translation",
    "max_input_tokens": 480,
    "target_chunk_tokens": 300,
    "overlap_tokens": 40,
    "table_content_detected": 0,
    "model_available": true,
    "translation_decision": "nllb_processing",
    "model_used": "facebook/nllb-200-3.3B",
    "quality_scores": {
      "overall": 0.928408152985428,
      "chunk_count": 2,
      "linguistic": {
        "fluency": 0.6818181818181819,
        "accuracy": 0.8626250884463762,
        "consistency": 0.971830985915493,
        "completeness": 0.9327496274217586,
        "linguistic_composite": 0.8442491037468177
      },
      "domain_specific": {
        "medical_terminology": 1.0,
        "numerical_integrity": 0.9264705882352942,
        "statistical_terms": 1.0,
        "unit_preservation": 1.0,
        "domain_composite": 0.9779411764705882
      },
      "structural": {
        "format_preservation": 1.0,
        "document_integrity": 1.0,
        "information_architecture": 1.0,
        "structural_composite": 1.0
      },
      "empty_translations": 0,
      "missing_content_ratio": 0.0
    },
    "translation_metadata": {
      "model_loaded": true,
      "model_name": "facebook/nllb-200-3.3B",
      "processing_time_seconds": 100.669122,
      "chunks_found": true,
      "total_chunks": 2,
      "chunks_translated": 3,
      "chunks_english": 0,
      "table_chunks_processed": 0,
      "quality_scores": {
        "overall": 0.928408152985428,
        "chunk_count": 2,
        "linguistic": {
          "fluency": 0.6818181818181819,
          "accuracy": 0.8626250884463762,
          "consistency": 0.971830985915493,
          "completeness": 0.9327496274217586,
          "linguistic_composite": 0.8442491037468177
        },
        "domain_specific": {
          "medical_terminology": 1.0,
          "numerical_integrity": 0.9264705882352942,
          "statistical_terms": 1.0,
          "unit_preservation": 1.0,
          "domain_composite": 0.9779411764705882
        },
        "structural": {
          "format_preservation": 1.0,
          "document_integrity": 1.0,
          "information_architecture": 1.0,
          "structural_composite": 1.0
        },
        "empty_translations": 0,
        "missing_content_ratio": 0.0
      }
    },
    "total_processing_time_seconds": 103.117308,
    "processing_completed_timestamp": "2025-08-11T12:18:59.263514"
  }
}